U.S. healthcare spending is the highest in the world, and the gap isn’t close. The country spends roughly twice per person what other high-income nations spend, yet consistently ranks lower on health outcomes. Decades of peer-reviewed research have converged on a set of interlocking drivers: administrative complexity, market consolidation, high prices for drugs and services, chronic disease burden, technology adoption, and systemic waste. Here’s what the evidence actually shows.
Administrative Complexity Is the Largest Single Factor
The U.S. spent $1,055 per person on healthcare governance and financing administration in 2020. The average across comparable wealthy nations was $193 per person, more than a fivefold difference. A 2023 Commonwealth Fund analysis found that administrative costs represent the single biggest component of excess U.S. spending compared to peer countries, accounting for roughly 30 percent of the total excess when combining insurance-side and provider-side costs.
About half of that burden falls on insurers. Processing eligibility checks, coding claims, submitting paperwork, and reworking denied claims all carry costs that are far lower in countries with simpler payment systems. The other half falls on hospitals and physician practices, which spend heavily on general administration, human resources, compliance, quality reporting, and accreditation. In a single-payer or tightly regulated multi-payer system, many of these tasks either don’t exist or are dramatically simplified. In the U.S., every hospital must navigate dozens of insurers, each with different rules, formularies, and prior authorization requirements.
Hospital Consolidation Drives Up Prices
When hospitals merge, the textbook promise is greater efficiency and lower costs. The actual evidence points in the opposite direction. The director of the Federal Trade Commission’s Bureau of Economics has stated that merged hospitals charge 40 to 50 percent more than they would have without consolidation. In markets that were already concentrated before a merger, the price increases can be even more dramatic.
This pattern is consistent across geographic regions and data sources. Even the insurance industry’s own trade group has acknowledged that consolidation delivers greater costs rather than greater efficiency. The mechanism is straightforward: fewer competing hospitals in a region means insurers have less leverage to negotiate prices down, and patients have fewer alternatives. The result is higher prices for the same services, with no consistent improvement in quality. A published review in Missouri Medicine concluded bluntly that hospital mergers produce systems that are “bigger but not better.”
Prices Vary Enormously for the Same Procedure
One of the most striking features of U.S. healthcare is the sheer randomness of what things cost. An analysis of commercial insurance data found that state-level prices for inpatient services vary by 174 percent, while outpatient services vary by 688 percent. A major joint replacement without complications averages about $31,000 in facility fees nationally, but the mean inpatient price ranges from roughly $12,900 in Mississippi to $35,400 in Vermont. Even a routine office visit costs $82 through one insurer and $115 through another for the identical service code.
These differences aren’t explained by differences in the cost of living or the complexity of care. They reflect the fragmented, opaque nature of price-setting in U.S. healthcare, where each hospital negotiates separate rates with each insurer, and patients rarely see those prices before receiving care.
Drug Prices Reflect Monopoly Power
Branded pharmaceuticals in the U.S. cost far more than in other countries, and the core reason is market structure. New drugs, from GLP-1 medications for diabetes and obesity to next-generation cancer treatments, are controlled by manufacturers that hold patent-protected monopolies. Unlike most other wealthy nations, the U.S. has historically lacked a centralized body that negotiates or caps drug prices, giving manufacturers significant power to set prices based on what the market will bear rather than what development cost.
Demand continues to grow as the population ages, chronic disease rates climb, and innovative treatments reach the market. Each of these forces pushes spending higher. The combination of monopoly pricing, expanding demand, and limited government negotiation creates a ratchet effect where drug spending rises year after year.
Chronic Disease Consumes 86 Percent of Spending
About half of the U.S. population lives with at least one chronic condition, including diabetes, heart disease, obesity, and respiratory illness. Care for these conditions consumes 86 percent of all healthcare expenditures. That figure alone explains much of the spending picture: the U.S. doesn’t just have expensive healthcare, it has a population that requires an enormous volume of ongoing care.
Chronic diseases require repeated office visits, long-term medications, monitoring, and often costly interventions when conditions worsen. Patients with multiple chronic conditions are especially expensive to treat, and their numbers are growing. This creates a feedback loop. High chronic disease prevalence drives high spending, and the system’s orientation toward treating acute episodes rather than prevention means less investment in the upstream factors (nutrition, housing, mental health) that could reduce chronic disease rates over time.
Technology Adoption Accounts for Half of Cost Growth
New medical technology, from advanced imaging equipment to robotic surgical systems and novel therapies, is one of the largest drivers of healthcare cost growth over time. A systematic review of econometric studies found that technology accounts for roughly 25 to 75 percent of the increase in healthcare spending, with most estimates centering around 50 percent. The U.S. adopts new technologies faster and more broadly than most other nations, which delivers clinical benefits but at a steep price.
The U.S. has about 35 MRI machines per million people, the highest density among the 16 countries tracked in one OECD comparison. Americans receive about 105 MRI exams per 1,000 people and roughly 220 CT scans per 1,000 people, rates that place the country near the top internationally. More machines and more scans don’t automatically mean better health. In many cases, the marginal scan catches nothing actionable but still generates a bill. The combination of high technology density, fee-for-service payment models that reward volume, and patient expectations creates a system that uses expensive tools liberally.
Physician Compensation Is Substantially Higher
U.S. physicians earn far more than their counterparts abroad. Average physician earnings in the U.S. are approximately $316,000 per year. In Germany, the next highest among major economies, the figure is $183,000. In the United Kingdom, it’s $138,000. In France, $98,000. These gaps are even wider for specialists in fields like orthopedic surgery and cardiology.
Higher physician compensation reflects several forces: the cost of U.S. medical education (graduates carry significant debt), the length of training, and the market dynamics of a system where specialists can command high fees from insurers. Physician pay is a meaningful contributor to overall spending, though it’s far from the largest one. It’s also one of the more politically sensitive cost drivers, since proposals to reduce physician compensation run headlong into concerns about medical education debt and workforce recruitment.
Defensive Medicine and Low-Value Care
Fear of malpractice lawsuits leads physicians to order tests and procedures that aren’t clinically necessary but serve as legal protection. This practice, known as defensive medicine, is estimated to cost roughly $46 billion annually. The true figure is difficult to pin down because distinguishing a defensively motivated test from a clinically warranted one often depends on context that claims data can’t capture.
Beyond defensive medicine, the healthcare system delivers a substantial volume of care that provides little or no benefit. An analysis of Medicare claims found that just 47 identified low-value services cost the program $3.6 billion per year, with patients paying an additional $800 million out of pocket. Five services that the U.S. Preventive Services Task Force explicitly recommends against accounted for 59 percent of that total, or $2.6 billion. These are screenings, tests, and procedures performed millions of times each year despite evidence that they don’t help and can cause harm through false positives, unnecessary follow-up procedures, and patient anxiety.
How These Factors Reinforce Each Other
No single factor explains U.S. healthcare costs. What makes the problem so persistent is that these drivers interact. Administrative complexity raises the cost of delivering every service, which makes chronic disease management more expensive, which inflates the spending totals that justify higher insurer premiums, which fund the administrative apparatus. Hospital consolidation reduces competition, which enables higher prices, which increases insurer costs, which gets passed to employers and patients. Technology adoption creates demand for more specialist visits, more imaging, and more follow-up care, each of which generates administrative and billing costs of its own.
The scholarly literature converges on a conclusion that health economists have summarized simply: “It’s the prices, stupid.” The U.S. doesn’t use dramatically more healthcare services than other wealthy countries across every category. It pays dramatically more for the services it does use, in a system where administrative overhead, market concentration, and fragmented pricing multiply the impact of every dollar spent.